Crescent Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	189.16	213.19	34.77	41.79	47.87	90.25
Cash & Short-Term Investments	189.16	213.19	34.77	41.79	47.87	90.25
Cash Growth	3269.37%	513.22%	-16.81%	-12.70%	-46.96%	-34.14%
Accounts Receivable	-	18	-	-	-	-
Other Current Assets	6.51	5.57	0.04	2	2.84	0.53
Total Current Assets	195.56	236.66	34.8	43.79	50.71	90.79
Net Property, Plant & Equipment	2.3	2.32	-	0.77	0.75	1.95
Other Long-Term Assets	1.16	1.22	0.81	0.76	0.34	1.61
Total Assets	199.13	240.29	35.62	45.32	51.81	94.35
Accounts Payable	1.19	10.14	7.33	0.87	0.97	2.11
Accrued Expenses	4.43	16.34	2.23	5.23	6.99	8.72
Current Portion of Leases	0.45	0.44	-	0.74	0.92	1
Unearned Revenue	3.12	4.16	-	-	-	-
Other Current Liabilities	5	5	0.06	-	-	-
Total Current Liabilities	14.19	36.07	9.61	6.84	8.88	11.82
Long-Term Debt	-	-	37.48	-	-	-
Long-Term Leases	1.09	1.21	-	-	-	-
Total Long-Term Liabilities	1.09	1.21	37.48	-	-	-
Total Liabilities	15.28	37.28	47.1	6.9	8.88	12.74
Preferred Stock	4	4	-	-	-	-
Common Stock	0.03	0.03	0	-	-	-
Total Common Shareholders' Equity	4.03	4.03	0	-	-	-
Minority Interest	-	-	4	-	-	-
Shareholders' Equity	179.82	198.98	-15.48	38.41	42.88	81.55
Total Liabilities & Equity	199.13	240.29	35.62	45.32	51.81	94.35
Total Debt	1.54	1.64	37.48	0.74	0.92	1
Net Cash (Debt)	187.62	211.55	-2.72	41.05	46.95	89.25
Net Cash Growth	-11.31%	-	-	-12.57%	-47.39%	-34.44%
Net Cash Per Share	10.57	20.32	-4.21	64.81	89.38	173.47
Book Value	4.03	4.03	0	0	0	0
Book Value Per Share	0.23	0.39	0.00	-	-	-
Tangible Book Value	4.03	4.03	0	0	0	0
Tangible Book Value Per Share	0.23	0.39	0.00	-	-	-

SEC Filings: 10-K · 10-Q